WALTHAM, Mass.--(BUSINESS WIRE)--NeuroMetrix, Inc. (NASDAQ:NURO) announced today that to celebrate having reached 10,000 fans for Quell® Pain Relief on Facebook, it will give away a contest prize each day during September which is Pain Awareness Month. Consumers are encouraged to follow the Quell Facebook page for details on how to enter the contest.
“The rapid growth of the Quell Facebook community is an indicator of the growing awareness and enthusiasm for our Quell Wearable Pain Relief Technology™ among consumers,” says Frank McGillin, NeuroMetrix Senior Vice President and General Manager, Consumer. “We value the opportunity to engage with existing and prospective Quell users and have been moved by the stories about how Quell is fundamentally impacting the quality of people’s lives.”
The Quell Pain Relief Facebook community has given Quell an average 4.6 star rating. Some recent reviewers have written:
- “Thank you so much for making this miracle pain relief device.” – Linda F.
- “I do love this thing!!!! I have gone from taking pain medication every 3 hours to just taking morning and evening. What a life changer.” – Debra R.
- “Thank you Quell for making me so happy with my life again!!!!!” – Kim M.
- “It really does work!!! I am certainly enjoying my pain free lifestyle, thank you Quell!!! I've got my life back!!!” – Doug P.
About Quell Wearable Pain Relief Technology
Quell is an easy-to-use, over-the-counter device for relief of chronic pain. This wearable device utilizes NeuroMetrix's patented technology to provide widespread pain relief. In a recent clinical study, Quell improved chronic pain in 81% of participants. Quell is currently available through select healthcare professionals, retailers, and online at www.QuellRelief.com.
NeuroMetrix is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders and diabetes. The company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs, including a therapeutic device for restless leg syndrome. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.